Market research
AEZS Aeterna Zentaris Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 15
- Dividend yield
- Not available
- Beta
- 2.26
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA0079754028
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 15
- Dividend yield
- Not available
- Beta
- 2.26
About
About Aeterna Zentaris Inc
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AEZS discussion.
5 years, 4 months ago
Aeterna Zentaris Inc is currently in a long term uptrend where the price is trading 9.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.6.
Aeterna Zentaris Inc's total revenue rose by 13044.4% to $2M since the same quarter in the previous year.
Its net income has dropped by 30.3% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 185.2% to $3M since the same quarter in the previous year.
Based on the above factors, Aeterna Zentaris Inc gets an overall score of 4/5.